SCHEMBL934572

SCHEMBL934572

NN(Cc1ccc(Cl)cc1)c1ccc(F)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2A1 Q16548 1/20 0.51
ESR1 P03372 1/20 0.49
ESR2 Q92731 1/20 0.49
CNR1 P21554 1/20 0.46
CNR2 P34972 1/20 0.46
MAPT P10636 2/20 0.42
THRB P10828 1/20 0.42
AOC3 Q16853 2/20 0.39
LOXL2 Q9Y4K0 1/20 0.39
PTPN1 P18031 1/20 0.39
CYP3A4 P08684 1/20 0.38
KMT2A Q03164 2/20 0.37
POLB P06746 1/20 0.37
RAB9A P51151 1/20 0.37
MEN1 O00255 1/20 0.37
GAA P10253 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CXCR3 P49682 1/20 0.36
TAAR1 Q96RJ0 2/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9457770 0.98 BCL2A1 (0.50) BCL2A1ESR1ESR2CNR1CNR2
SCHEMBL9737481 0.90 AOC3 (0.45) BCL2A1CNR1CNR2AOC3RAB9A
SCHEMBL933733 0.90 ESR1 (0.57) BCL2A1ESR1ESR2AOC3LOXL2
Hydrochloric Acid SCHEMBL9518394 0.88 AOC3 (0.44) BCL2A1CNR1CNR2AOC3RAB9A
SCHEMBL990626 0.82 AOC3 (0.53) BCL2A1ESR1ESR2CNR1CNR2
SCHEMBL989860 0.82 AOC3 (0.53) BCL2A1ESR1ESR2CNR1CNR2
SCHEMBL934617 0.81 ESR1 (0.49) ESR1ESR2AOC3LOXL2GAA
SCHEMBL9737153 0.81 GBA1 (0.41) AOC3KMT2AMEN1SMN1; SMN2TAAR1
SCHEMBL9735994 0.81 CNR2 (0.48) CNR1CNR2AOC3KMT2APOLB
SCHEMBL9879437 0.81 SLC6A2 (0.47) CNR1CNR2AOC3KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9983218-B2 Indole and indoline derivatives and methods of use thereof ABBVIE INC. (US) 2018-05-29 US disclosed
US-20180024144-A1 INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF ABBVIE INC. (US) 2018-01-25 US disclosed
US-9625475-B2 Indole and indoline derivatives and methods of use thereof ABBVIE INC. (US) 2017-04-18 US disclosed
US-20150353550-A1 INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF ABBVIE INC (US) 2015-12-10 US disclosed
US-9063126-B2 Indole and indoline derivatives and methods of use thereof ABBVIE INC. (US) 2015-06-23 US disclosed
EP-2344505-A2 INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF Abbott Laboratories (US) 2011-07-20 EP disclosed
WO-2011008312-A2 INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2011-01-20 WO disclosed
US-20100249105-A1 INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2010-09-30 US disclosed
US-20100087471-A1 INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2010-04-08 US disclosed
WO-2010036998-A2 INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2010-04-01 WO disclosed
US-5081145-A Contractile prostaglandin antagonists MERCK FROSST CANADA, INC. (CA) 1992-01-14 US disclosed
US-4940719-A Tetrahydrocarbazole esters, pharmaceutical compositions and use MERCK FROSST CANADA, INC. (CA) 1990-07-10 US disclosed
EP-0166591-B1 INDOLE-2-ALKANOIC ACIDS AND THEIR USE AS PROSTAGLANDIN ANTAGONISTS MERCK FROSST CANADA INC. (CA) 1989-11-23 EP disclosed
EP-0300676-A2 Tetrahydrocarbazole 1-alkanoic acids MERCK FROSST CANADA INC. (CA) 1989-01-25 EP disclosed
EP-0166591-A2 Indole-2-alkanoic acids and their use as prostaglandin antagonists MERCK FROSST CANADA INC. (CA) 1986-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249105-A1 INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF IDO1, IDO2, TPH1 BCL2A1 2454/4885ESR1 1490/4885ESR2 1148/4885
US-20180024144-A1 INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF IDO1, IDO2, TPH1 BCL2A1 2454/4885ESR1 1490/4885ESR2 1148/4885
US-20100087471-A1 INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF IDO1, IDO2, TPH1 BCL2A1 2454/4885ESR1 1490/4885ESR2 1148/4885
US-20150353550-A1 INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF IDO1, IDO2, TPH1 BCL2A1 2454/4885ESR1 1490/4885ESR2 1148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.